The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Open accessAbstract
Current success of immunotherapy in cancer has drawn attention to the subsets of T H cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presence of immunosuppressive pro-tumorigenic T H subsets in the tumor milieu further contributes to the complexity of regulation of T H cell-mediated immune response. In this review, we present an overview of the multifaceted positive and negative effects of T H cells, with an emphasis on regulation of different T H cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy. We focus on the regulatory network that encompasses dendritic cell-induced activation of CD4+T H 1 cells and subsequent priming of CD8+cytotoxic T cells, along with intersecting anti-inflammatory and pro-tumorigenic T H 2 cell activity. We further discuss how other tumor infiltrating immune cells such as immunostimulatory T H 9 and T fh cells, immunosuppressive T reg cells, and the duality of T H 17 function contribute to tip the balance of anti- vs pro-tumorigenic T H responses in the tumor. We highlight the developing knowledge of CD4+T H 1 immune response against neoantigens/oncodrivers, impact of current immunotherapy strategies on CD4+T H 1 immunity, and how opposing action of T H cell subtypes can be explored further to amplify immunotherapy success in patients. Understanding the nuances of CD4+T H cells regulation and the molecular framework undergirding the balancing act between anti- vs pro-tumorigenic T H subtypes is critical for rational designing of immunotherapies that can bypass therapeutic escape to maximize the potential of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–229 of 229
Bretscher, P. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01234 · Cited by 57
Costa, R. L. B., Soliman, H. H., & Czerniecki, B. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.005 · Cited by 56
Self-citationGiltnane, J. M., Moeder, C. B., Camp, R. L., & Rimm, D. L. (2009) · Cancer · doi:10.1002/cncr.24277 · Cited by 55
Kodumudi, K. N., Ramamoorthi, G., Snyder, C., Basu, A. B., Jia, Y., Awshah, S., Beyer, A., Wiener, D. A., Lam, L., Zhang, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01939 · Cited by 55
Self-citationSalomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 53
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Peng, P., Hu, H., Liu, P., & Xu, L. X. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000421 · Cited by 51
Th17 cells have stem cell-like features and promote long-term immunity
Wei, S., Zhao, E., Kryczek, I., & Zou, W. (2012) · OncoImmunology · doi:10.4161/onci.19440 · Cited by 50
Th Cells Act Via Two Synergistic Pathways To Promote Antiviral CD8+ T Cell Responses
Wiesel, M., Joller, N., Ehlert, A.-K., Crouse, J., Spörri, R., Bachmann, M. F., & Oxenius, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001990 · Cited by 48
Goods, B. A., Hernandez, A., Lowther, D. E., Lucca, L. E., Lerner, B. A., Günel, M., Raddassi, K., Coric, V., Hafler, D. A., & Love, J. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181538 · Cited by 43
Sacks, J. A., & Bevan, M. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4570 · Cited by 41
Park, J. M., Terabe, M., Steel, J. C., Forni, G., Sakai, Y., Morris, J. C., & Berzofsky, J. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5688 · Cited by 41
Clinical Development of the E75 Vaccine in Breast Cancer
Clifton, G. T., Gall, V., Peoples, G. E., & Mittendorf, E. A. (2016) · Breast Care · doi:10.1159/000446097 · Cited by 40
Rosemblit, C., Datta, J., Lowenfeld, L., Xu, S., Basu, A. B., Kodumudi, K. N., Wiener, D. A., & Czerniecki, B. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25208 · Cited by 39
Self-citationIL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells duringex vivoexpansion
Knutson, K. L., & Disis, M. L. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02360.x · Cited by 35
Self-citationDatta, J., Xu, S., Rosemblit, C., Smith, J. B., Cintolo, J. A., Powell, D. J., & Czerniecki, B. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0208 · Cited by 33
Self-citationMagbanua, M. J. M., Rugo, H. S., Hauranieh, L., Roy, R., Scott, J. H., Lee, J. C., Hsiao, F., Sosa, E. V., Veer, L. V., Esserman, L. J., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0083-5 · Cited by 33
Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression
Wolkers, M. C., Gerlach, C., Arens, R., Janssen, E. M., Fitzgerald, P., Schumacher, T. N., Medema, J. P., Green, D. R., & Schoenberger, S. P. (2011) · Blood · doi:10.1182/blood-2011-08-373910 · Cited by 32
(2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6548-9 · Cited by 32
Adotévi, O., Dosset, M., Galaine, J., Beziaud, L., Godet, Y., & Borg, C. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23587 · Cited by 29
Pathangey, L. B., McCurry, D., Gendler, S. J., Dominguez, A. L., Gorman, J. E., Pathangey, G., Mihalik, L. A., Dang, Y., Disis, M. L., & Cohen, P. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13911 · Cited by 26
Self-citationCombination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 26
Eddine, F. B. N., Ramia, E., Tosi, G., Forlani, G., & Accolla, R. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356149 · Cited by 23
Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy
Chen, J., Zhao, Y., Chu, X., Lu, Y., Wang, S., & Yi, Q. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238558 · Cited by 21
Fracol, M. E., Datta, J., Lowenfeld, L., Xu, S., Zhang, P. J., Fisher, C. S., & Czerniecki, B. J. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5584-6 · Cited by 17
Self-citationCD4 + follicular helper-like T cells are key players in anti-tumor immunityPreprint
Singh, D. K., Ganesan, A., Panwar, B., Eschweiler, S., Hanley, C. J., Madrigal, A., Ramírez-Suástegui, C., Wang, A., Clarke, J. D., Wood, O., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.08.898346 · Cited by 14
Showalter, L. E., Czerniecki, B. J., & Koski, G. K. (2020) · Oncotarget · doi:10.18632/oncotarget.27556 · Cited by 13
Self-citationRole of Th9 cells and Th17 cells in the pathogenesis of malignant ascites
Yang, X., Jiang, H., Huang, X., Ma, S.-J., & Qin, S. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2015.07.013 · Cited by 4
Qu, C., Chen, K., & Cheng, S. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.12 · Cited by 1
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009517 · Cited by 43
Metadata
- Authors
- Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-03
- Volume
- 12
- Pages
- 669474-669474
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3158086066
- Cited by
- 321
- References
- 229
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.